ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1630862
Study of the predictive value of testosterone in androgen deprivation therapy for metastatic hormone sensitive prostate cancer—the dual clinical research centre for western and eastern China
Provisionally accepted
- 1Department of Reproductive Medicine, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, China
- 2Department of Reproductive Medicine, The People's Hospital Bozhou, Bozhou, China
- 3Reproductive male laboratory, The People's Hospital Bozhou, Bozhou, China
- 4Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the association between early testosterone (T) response to androgen deprivation therapy (ADT) and clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC). Results: No significant intergroup differences were observed in Gleason score, tumor stage, prostate volume, initial PSA, PSA density, perineural invasion, visceral metastasis, or hazard level (all P>0.05). However, the T non-response group exhibited higher tumor load prevalence (76.77% vs 60.10%, P=0.004). The T non-response group demonstrated shorter mCRPC progression time (13.38 ± 8.88 vs 20.40 ± 11.91 months, P < 0.001), though no difference emerged between T ultra-low and low response subgroups (20.59 ± 11.91 vs 20.86 ± 12.19 months, P = 0.876). Survival analysis revealed superior 3-year survival in T responders (P = 0.024), with T ultra-low responders showing significant advantages in both overall survival (P = 0.010) and 3-year survival (P = 0.001) compared to T low responders. Conclusion: Ultra-low T levels ( <20ng/dl) after ADT 1-month, can be used as a reference standard for predicting survival outcomes and may guide treatment optimization in mHSPC.
Keywords: prostate cancer, Testosterone, androgen deprivation therapy, metastatic hormone sensitive prostate cancer, Testosterone response
Received: 18 May 2025; Accepted: 01 Oct 2025.
Copyright: © 2025 Ma, Zhang and Xi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianhong Xi, 844822376@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.